Leprosy drug clofazimine activates peroxisome proliferator-activated receptor-γ and synergizes with imatinib to inhibit chronic myeloid leukemia cells.

Analysis of tumor volume revealed a decreasing trend in all treatment groups which although not statistically significant (except for the imatinib group in which the tumor volume was statistically significantly reduced on day 13), became so after removal of an outlier (starting tumor volume >150 mm 3 , marked as red ‘O’, Figure 8A ) in the clofazimine + imatinib group in which the reduction in tumor volume was statistically significant from day 9 onwards, while that in the imatinib group was statistically significant on day 13 only ( Figure 8A, B ).

also in 47,180 other papers